Table 4.
Concordance of pre-assay treatment decisions between physicians and patients.
| Pre-assay Physician Recommendations | Pre-assay Patient Decisions | |||||
|---|---|---|---|---|---|---|
| Observation | 5FU-based monotherapy | 5FU+Oxaliplatin | Other | Undecided | Total | |
| Observation | 39 28.3% |
0 | 0 | 2 1.4% |
22 15.9% |
63 45.7% |
| 5FU-based monotherapy | 11 8.0% |
2 1.4% |
1 0.7% |
3 2.8% |
17 12.3% |
34 24.6% |
| 5FU +Oxaliplatin | 12 8.7% |
1 0.7% |
8 5.8% |
0 | 14 10.1% |
35 25.4% |
| Other | 2 1.4% |
1 0.7% |
0 | 0 | 3 2.8% |
6 4.3% |
| Total | 64 46.4% |
4 2.9% |
9 6.5% |
5 3.6% |
56 40.6% |
138 100.0% |